Scribe Therapeutics Gains Approval for First Human Trial of LDL-C Reducing Therapy
Scribe Therapeutics, a biotechnology company based in Alameda, California, has received regulatory clearance from the Australian Therapeutic Goods Administration to begin a first-in-human clinical study of STX-1150. This investigational therapy aims to reduce low-density lipoprotein cholesterol (LDL-C) by epigenetically silencing the PCSK9 gene, a key regulator of cholesterol. The therapy uses Scribe's proprietary ELXR technology to achieve long-lasting gene silencing in the liver without altering DNA permanently. The Phase 1 study will assess the safety, tolerability, and efficacy of STX-1150 in adults with elevated LDL-C, with trial sites in Australia and New Zealand. 
